May 7, 2024
Making a positive impact
When University of Missouri senior Grace Liles enrolled at Mizzou, one of the world’s leading research institutions, she joined the chemistry fraternity Alpha Chi Sigma.
April 5, 2024
MITC administratively realigns under MU Research Reactor
The change will allow for consistent staff training, a cohesive and vibrant safety culture and dedicated facility support.
April 3, 2024
Innovative yttrium-90 radioisotopes revolutionize liver cancer treatment
Yttrium-90 radioisotopes produced at the University of Missouri Research Reactor are extending and improving the lives of patients with liver cancer.
Feb. 27, 2024
Adding a radioisotope to the toolkit for saving lives
A pair of University of Missouri researchers study terbium-161 with the hope that one day it could be the next major radioisotope produced to treat cancer.
Dec. 14, 2023
MU Health Care pilots breakthrough treatment for prostate cancer
Treatment uses radioisotopes produced in the University of Missouri Research Reactor.
Dec. 8, 2023
MU Research Reactor announces commercial shipments of breakthrough radioisotope for cancer treatment
The University of Missouri Research Reactor (MURR) is the only U.S. supplier of the radioisotope, produced using a propriety process developed at MURR.
Nov. 7, 2023
Tiny atoms, big impact: How the MU Research Reactor is saving and improving lives in Missouri and around the globe
NextGen MURR initiative will expand the University of Missouri’s capacity to produce medical isotopes that will be used in advanced cancer treatments for decades to come.
Oct. 3, 2023
University of Missouri breaks ground on addition to MU Research Reactor facility
The new $20 million, three-story addition to the existing MURR North Building will expand the facility’s production space and testing laboratories.
July 17, 2023
University of Missouri Research Reactor continues to bolster domestic supply chain of critical radioisotopes
New production of iron and manganese radioisotopes creates domestic supply for researchers and Department of Energy.
June 23, 2023
MU Research Reactor announces FDA submission for new radioisotope process for cancer therapy
If approved, the new proprietary no-carrier-added lutetium-177 process will expand MURR’s production of cutting-edge radioisotopes used in lifesaving cancer treatments.